Skip to main content
Erschienen in: Acta Diabetologica 4/2014

01.08.2014 | Original Article

Duration of diabetes and effectiveness of insulin in the management of insulin-naïve Korean patients uncontrolled on oral antidiabetic drugs: a sub-analysis of the MOdaliTy of Insulin treatment eValuation (MOTIV) registry results

verfasst von: Sang Soo Kim, In Joo Kim, Yong Ki Kim, Kun Ho Yoon, Ho Young Son, Sung Woo Park, Yeon Ah Sung, Hong Sun Baek, Kyoung Soo Ha

Erschienen in: Acta Diabetologica | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

To investigate whether duration of diabetes has an impact on the effectiveness of insulinization in diabetes management. This open-label, noninterventional, observational registry was conducted at >500 centers in Korea. Patients with diabetes, on oral antidiabetic drugs, with HbA1c ≥7 % (53 mmol/mol) in the preceding 3 months, being considered for initiation of basal insulin by their physicians, were included. Data were collected at baseline and at 3 and 6 months. Of 6,616 patients evaluated, 62.5 % had diabetes for <10 years, while only 6.5 % patients had diabetes for ≥20 years. At the end of study, average HbA1c in patients with diabetes for <10 years, for 10 to <20 years, and for ≥20 years was 7.3 ± 1.0 % (56 ± 10.9 mmol/mol), 7.4 ± 1.0 % (57 ± 10.9 mmol/mol), and 7.6 ± 1.1 % (60 ± 12.0 mmol/mol), respectively. Over half the patients (50.7 %) with diabetes <10 years achieved HbA1c <7 % (53 mmol/mol) by the end of study, while only 42.1 and 35.1 % patients with diabetes for 10 to <20 and ≥20 years, respectively, achieved their target. The average insulin dosage required for per unit HbA1c reduction was significantly different among the groups according to duration of type 2 diabetes mellitus (p < 0.05). Among patients who achieved HbA1c <7 %, proportion of patients with hypoglycemia in the ≥20 years group was higher than that in the <10 years, 10 to <20 years groups. Early insulin administration provided a better glycemic control with less insulin dosage and lower frequency of hypoglycemic events. Thus, early insulinization might hold the key to better management of type 2 diabetes mellitus.
Literatur
4.
Zurück zum Zitat Lim S, Kim DJ, Jeong IK et al (2009) A nationwide survey about the current status of glycemic control and complications in diabetic patients in 2006: the committee of the Korean diabetes association on the epidemiology of diabetes mellitus. Korean Diabetes J 33:48–57CrossRef Lim S, Kim DJ, Jeong IK et al (2009) A nationwide survey about the current status of glycemic control and complications in diabetic patients in 2006: the committee of the Korean diabetes association on the epidemiology of diabetes mellitus. Korean Diabetes J 33:48–57CrossRef
5.
Zurück zum Zitat Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379PubMedCentralPubMedCrossRef Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Jabbour S (2008) Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both? Int J Clin Pract 62:845–847PubMedCrossRef Jabbour S (2008) Primary care physicians and insulin initiation: multiple barriers, lack of knowledge or both? Int J Clin Pract 62:845–847PubMedCrossRef
7.
Zurück zum Zitat Riedel AA, Heien H, Wogen J, Plauschinat CA (2007) Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. Am J Manag Care 13:457–463PubMed Riedel AA, Heien H, Wogen J, Plauschinat CA (2007) Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen. Am J Manag Care 13:457–463PubMed
8.
Zurück zum Zitat Riedel AA, Heien H, Wogen J, Plauschinat CA (2007) Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 27:1102–1110PubMedCrossRef Riedel AA, Heien H, Wogen J, Plauschinat CA (2007) Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy. Pharmacotherapy 27:1102–1110PubMedCrossRef
9.
Zurück zum Zitat Brown JB, Nichols GA, Perry A (2004) The burden of treatment failure in type 2 diabetes. Diabetes Care 27:1535–1540PubMedCrossRef Brown JB, Nichols GA, Perry A (2004) The burden of treatment failure in type 2 diabetes. Diabetes Care 27:1535–1540PubMedCrossRef
10.
Zurück zum Zitat Vinik A (2007) Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther 29:1236–1253CrossRef Vinik A (2007) Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther 29:1236–1253CrossRef
12.
Zurück zum Zitat Tsai ST, Pathan F, Ji L et al (2011) First insulinization with basal insulin in patients with type 2 diabetes in a real-world setting in Asia. J Diabetes 3:208–216PubMedCentralPubMedCrossRef Tsai ST, Pathan F, Ji L et al (2011) First insulinization with basal insulin in patients with type 2 diabetes in a real-world setting in Asia. J Diabetes 3:208–216PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, ATLANTUS Study Group (2005) Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28:1282–1288PubMedCrossRef Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, ATLANTUS Study Group (2005) Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 28:1282–1288PubMedCrossRef
14.
Zurück zum Zitat Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080–3086PubMedCrossRef Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators (2003) The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080–3086PubMedCrossRef
15.
Zurück zum Zitat Dailey GE 3rd (2005) Early insulin: an important therapeutic strategy. Diabetes Care 28:220–221PubMedCrossRef Dailey GE 3rd (2005) Early insulin: an important therapeutic strategy. Diabetes Care 28:220–221PubMedCrossRef
16.
Zurück zum Zitat Davidson MB (2005) Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care 28:222–224PubMedCrossRef Davidson MB (2005) Early insulin therapy for type 2 diabetic patients: more cost than benefit. Diabetes Care 28:222–224PubMedCrossRef
17.
Zurück zum Zitat Home PD, Boulton AJM, Jimenez J, Landgraf R, Osterbrink B, Christiansen JS (2003) Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diabetes Int 20:63–71CrossRef Home PD, Boulton AJM, Jimenez J, Landgraf R, Osterbrink B, Christiansen JS (2003) Issues relating to the early or earlier use of insulin in type 2 diabetes. Pract Diabetes Int 20:63–71CrossRef
18.
Zurück zum Zitat Peyrot M, Rubin RR, Lauritzen T et al (2005) Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care 28:2673–2679PubMedCrossRef Peyrot M, Rubin RR, Lauritzen T et al (2005) Resistance to insulin therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care 28:2673–2679PubMedCrossRef
19.
Zurück zum Zitat ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328PubMedCrossRef ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR et al (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328PubMedCrossRef
Metadaten
Titel
Duration of diabetes and effectiveness of insulin in the management of insulin-naïve Korean patients uncontrolled on oral antidiabetic drugs: a sub-analysis of the MOdaliTy of Insulin treatment eValuation (MOTIV) registry results
verfasst von
Sang Soo Kim
In Joo Kim
Yong Ki Kim
Kun Ho Yoon
Ho Young Son
Sung Woo Park
Yeon Ah Sung
Hong Sun Baek
Kyoung Soo Ha
Publikationsdatum
01.08.2014
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 4/2014
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-014-0572-4

Weitere Artikel der Ausgabe 4/2014

Acta Diabetologica 4/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.